Piper Sandler analyst Edward Tenthoff reiterated an Overweight rating and $155 target on Alnylam (ALNY) after the company and Vir (VIR) expanded an existing collaboration to develop novel siRNA targeting SARS-CoV-2, the viral strain that causes COVID-19 infection. Alnylam has synthesized more than 350 siRNAs targeting SARS-CoV and SARS-CoV-2 genomes and will begin in vitro screening, at which point Vir then select potent siRNA for further preclinical screening and nominate a development candidate for clinical studies and commercialization. Alnylam is eligible for milestones and royalties under the agreement, Tenthoff says, adding that he expects FDA approval of lumasiran for primary hyperoxaluria type 1 by YE20 and in Europe in 2021.

ProQR Therapeutics (PRQR) announced the Annual General Meeting, AGM, of Shareholders will take place on Wednesday, May 22, 2024 at the offices of Allen & Overy LLP, in Amsterdam, the Netherlands. As part of the AGM, Martin Maier, PhD, is nominated for appointment as a non-executive Board Member for a period of four years. Dr. Maier is Senior Vice President Research heading the Oncology group at Alnylam Pharmaceuticals (ALNY).